Whose burden, whose benefit? Revisiting ethical trade-offs in the WHO guidelines on scaling up mass azithromycin administration.

New evidence suggests that mass drug administration of azithromycin (MDAA) can significantly reduce childhood mortality in high-burden, low-resource settings, yet the World Health Organization's (WHO) 2020 guidelines take a cautious approach due to concerns about antimicrobial resistance (AMR).While...

Descripció completa

Dades bibliogràfiques

Autors principals:	Maple Goh, A M Viens, Safura Abdool Karim, Aaron S Kesselheim, Kevin Outterson
Format:	Artigo
Idioma:	Inglês
Publicat:	Public Library of Science (PLoS) 2025-09-01
Col·lecció:	PLoS Medicine
Accés en línia:	https://doi.org/10.1371/journal.pmed.1004736
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!